Trial Profile

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms REMNANT

Most Recent Events

12 Dec 2023 Results(As of July 18 th 2023, 291 patients are enrolled in part 1 and 97 in part 2) presented at the 65th American Society of Hematology Annual Meeting and Exposition
20 Sep 2022 Planned End Date changed from 1 Jun 2031 to 1 Jun 2032.
20 Sep 2022 Planned primary completion date changed from 1 Jun 2030 to 1 Jun 2031.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com